证券代码：002626 证券简称：金达威 20211202 投资者关系活动记录表 编号：20211202 | --- | --- | --- | |----------------|-----------------------------------|----------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他 | | | | 国信证券 汪炳煌 | | | | | 海南龙吟虎啸私募基金管理中心（有限合伙）胡雄威 | | | 福建丹金恒信资产管理有限公司 | 乔颖 张玲君 | | 参与单位名称及 | 厦门财富管理有限公司 | 卢杰 | | 人员姓名 | 南方红石（厦门）资产管理有限公司 | 庄伟煌 | | | 厦门年赢投资咨询有限公司 | 李波 | | | 及个人投资者 22 名 | | | 时间 | 2021 年 12 月 02 日下午 | | | 地点 ...

证券代码：002626 证券简称：金达威 20221118 投资者关系活动记录表 编号：20221118 | --- | --- | --- | |-------------------------|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | □现场参观 | | | 类别 | □其他 | | | | 招商证券 食品饮料分析师 | 于佳琦、田地、陈书慧 | | 参与单位名称及 人员姓名 | 南方基金 赵舜 华夏基金 李柄桦 汇添富基金 田立 | | | | 国泰基金 智健 | | | | | | | | | | | 时间 地点 | 2022 年 11 ...

Financial Performance - The company's revenue for Q3 2022 was ¥740,469,478, a decrease of 20.18% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥74,398,530.52, down 53.08% year-on-year[5]. - Basic earnings per share for Q3 2022 were ¥0.12, reflecting a decrease of 53.85% year-on-year[5]. - Net profit for Q3 2022 was approximately ¥340.28 million, a decrease of 48.58% compared to ¥661.81 million in the same period last year[14]. - The total profit for Q3 2022 was CNY 410.30 million, down 47.5% from CNY 781.20 million in the same period last year[30]. - The company's operating profit for Q3 2022 was CNY 412.73 million, a decline of 47.9% from CNY 791.89 million in Q3 2021[30]. - The total comprehensive income for Q3 2022 was CNY 550.06 million, a decrease of 19.7% from CNY 685.69 million in the same quarter last year[30]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥428,821,982.31, a decline of 32.95% compared to the previous year[5]. - Operating cash flow for the period was ¥428.82 million, down 32.95% from ¥639.54 million year-on-year, primarily due to a decrease in cash received from sales[14]. - The cash and cash equivalents net decrease was ¥153.59 million, a 67.90% increase in outflow compared to ¥91.48 million in the same period last year[14]. - The net cash flow from operating activities for Q3 2022 was CNY 428.82 million, down 33% from CNY 639.54 million in Q3 2021[33]. - The company reported a net cash outflow from investing activities of CNY 245.04 million in Q3 2022, compared to a net outflow of CNY 266.08 million in Q3 2021[33]. - The cash outflow from financing activities in Q3 2022 was CNY 781.99 million, slightly lower than CNY 814.88 million in Q3 2021[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,138,217,880.48, an increase of 4.97% from the end of the previous year[5]. - Total liabilities rose to CNY 1,961,883,371.45, compared to CNY 1,820,794,793.46 in the previous year[24]. - The company's total equity rose to CNY 4,176,334,509.03, compared to CNY 4,026,997,342.66 last year[25]. - Cash and cash equivalents decreased to CNY 619,335,863.59 from CNY 769,560,917.83[22]. - Inventory increased significantly to CNY 993,880,971.79, up from CNY 833,737,379.18[22]. Shareholder Information - The company’s major shareholder, Xiamen Jindawei Investment Co., Ltd., holds 34.34% of the shares, totaling 211,712,732 shares[16]. - The top ten shareholders collectively hold a significant portion of the company, with the largest shareholder having a pledged share status of 49,511,500 shares[16]. - The company has no known related party relationships among the top ten shareholders, ensuring independent shareholder actions[18]. Income and Expenses - Other income increased by 43.09% to ¥13,986,560.15, mainly due to an increase in government subsidies related to normal operations[12]. - The company recorded a 44.75% rise in investment income, reaching ¥4,308,248.68, influenced by equity method investments and changes in financial assets[12]. - The company reported a significant decrease in non-operating income, down 60.88% to ¥880,866.14, primarily due to a reduction in government subsidies compared to the previous year[12]. - Total tax expenses decreased by 41.35% to ¥70.02 million from ¥119.39 million, mainly due to a decline in total profit[14]. - The company’s other comprehensive income after tax increased by 779.12% to ¥206.85 million, influenced by foreign currency translation differences[14]. Borrowings - The company experienced a 54.67% increase in short-term borrowings, totaling ¥258,937,726.32, primarily due to increased bank loans[12]. - Long-term borrowings increased to CNY 699,491,644.25 from CNY 628,389,454.31[24].

Financial Performance - The company reported a net profit of 300 million RMB for the first half of 2022, with a net profit margin of 20%[36]. - The company's operating revenue for the reporting period was ¥1,564,430,600, a decrease of 11.96% compared to the same period last year, which was ¥1,776,962,820.59[42]. - The net profit attributable to shareholders was ¥274,306,819.79, reflecting a significant decline of 45.87% from ¥506,734,950.48 in the previous year[42]. - The net profit after deducting non-recurring gains and losses was ¥271,545,225.35, down 43.26% from ¥478,580,881.93 year-on-year[42]. - The net cash flow from operating activities was ¥267,060,852.64, a decrease of 34.75% compared to ¥409,302,008.93 in the same period last year[42]. - Basic and diluted earnings per share were both ¥0.45, down 45.78% from ¥0.83 in the previous year[42]. - The weighted average return on net assets was 6.68%, down 7.08% from 13.76% in the previous year[42]. - The company achieved a revenue of 1.564 billion yuan in the first half of 2022, a decrease of 11.96% year-on-year[60]. - Net profit attributable to shareholders was 274 million yuan, down 45.87% year-on-year, while the net profit excluding non-recurring items was 272 million yuan, a decrease of 43.26% year-on-year[60]. Market and Competitive Landscape - The competitive landscape in the nutritional health food market is intensifying, with pressures from both domestic and international competitors[11]. - The global consumer health supplement market reached $273.24 billion in 2021, with China holding a 16.26% share, indicating significant growth potential in the industry[53]. - The company is the largest global producer of coenzyme Q10 and one of the top three producers of vitamin D3, with significant market presence in various international e-commerce platforms[56]. - The company has established a strategic partnership with Jinan University for clinical research on NMN products, which are gaining global attention[64]. - The company has a comprehensive product matrix covering dietary supplements, protein nutrition drinks, and various health products, catering to diverse consumer needs[58]. Sales and Distribution - The company's sales in domestic markets were ¥311,467,078.95, representing 19.91% of total revenue, while overseas sales accounted for ¥1,252,963,521.05, or 80.09%[98]. - The company’s online direct sales primarily rely on cross-border e-commerce platforms like Tmall International, JD.com, and Pinduoduo, covering multiple brands and products[77]. - The company generated total sales revenue of RMB 195,587,670.75 from its top distributor, accounting for 12.50% of total sales, with accounts receivable of RMB 73,725,074.16[76]. - The total revenue from the second-largest distributor was RMB 147,292,346.60, representing 9.42% of total sales, with accounts receivable of RMB 7,241,479.13[76]. Research and Development - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative health products and technologies[36]. - The company invested ¥41,118,398.68 in R&D, an increase of 17.55% compared to ¥34,980,924.24 in the previous year, reflecting increased investment in new product development[92]. - The company obtained 15 patent certificates during the reporting period, including 13 invention patents and 2 utility model patents, bringing the total authorized patents to 150 as of June 30, 2022[85]. Environmental and Social Responsibility - The company invested CNY 4.8079 million in environmental protection measures, including wastewater treatment facilities designed to handle 1,000 m³/d[147]. - The company emphasizes environmental protection and has implemented energy-saving and emission-reduction activities, focusing on becoming a resource-saving and environmentally friendly enterprise[168]. - The company has committed to maintaining a safe and comfortable working environment for employees, including annual health check-ups and training opportunities[168]. - The company has achieved compliance in all reported emissions, including VOCs and nitrogen oxides[144]. Strategic Plans and Future Outlook - The company plans to expand its product line with the introduction of three new dietary supplements by Q4 2022, targeting a market growth of 25% in this segment[36]. - The company aims for a compound annual growth rate (CAGR) of 18% over the next five years, driven by market expansion and new product launches[36]. - The company plans to continue expanding its market presence through new product development and strategic acquisitions in the health and wellness sector[106]. - The company has set a performance guidance of 3 billion RMB in revenue for the full year 2022, reflecting a 15% increase compared to 2021[36]. Risk Management - The company faces risks from raw material price volatility, which significantly affects production costs and overall profitability[8]. - The company is committed to monitoring and managing environmental protection costs due to increasing regulatory standards[12]. - The company is actively preparing for potential risks associated with its overseas subsidiaries, including political and legal challenges[15]. - The company has established management systems for foreign exchange hedging and interest rate swaps to control risks[120]. Corporate Governance - The company has established a sound corporate governance structure to protect shareholder and creditor rights[164]. - The company has implemented a comprehensive human resources management system, ensuring timely payment of wages and social insurance contributions[164]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[172].

Revenue and Profit - Revenue for Q1 2022 was CNY 741,447,582.31, a decrease of 17.74% compared to CNY 901,327,384.06 in the same period last year[4] - Net profit attributable to shareholders was CNY 120,327,135.61, down 59.91% from CNY 300,175,535.25 year-on-year[4] - Basic earnings per share decreased to CNY 0.20, a decline of 59.18% compared to CNY 0.49 in the previous year[4] - The total profit for the first quarter of 2022 was approximately ¥148.41 million, a decrease of 58.71% compared to the same period last year[10] - Net profit for the first quarter was approximately ¥121.12 million, reflecting a decline of 60.00% year-over-year[10] Cash Flow - Cash flow from operating activities was CNY 108,367,740.00, down 29.79% from CNY 154,337,231.51 in the same period last year[4] - Cash inflow from operating activities totaled ¥705,873,244.92, down 20.3% from ¥885,348,330.89 in the previous period[30] - The net cash flow from operating activities for Q1 2022 was ¥108,367,740, a decrease of 29.8% compared to ¥154,337,231 in Q1 2021[32] - The total cash outflow from investing activities was ¥178,334,913.25, significantly higher than ¥47,321,630.46 in the previous year, resulting in a net cash flow from investing activities of -¥131,834,560.46[32] - The cash flow from financing activities showed a net outflow of -¥251,288,273.67, compared to -¥55,061,951.29 in Q1 2021, indicating increased financing costs[34] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 5,709,846,857.71, a decrease of 2.36% from CNY 5,847,792,136.12 at the end of the previous year[5] - Current assets totaled RMB 2,044,135,194.47, down from RMB 2,122,706,980.02 at the beginning of the year, reflecting a decrease of approximately 3.69%[18] - Total liabilities decreased to RMB 1,565,071,986.66 from RMB 1,820,794,793.46, a reduction of approximately 14.03%[22] - The company's equity attributable to shareholders increased to RMB 4,086,043,705.92 from RMB 3,970,556,485.97, reflecting an increase of about 2.91%[22] Expenses - R&D expenses increased by 45.02% to CNY 21,511,080.15 compared to CNY 14,833,193.24 in the previous year[8] - Financial expenses surged by 366.74% to CNY 8,038,601.79, primarily due to changes in exchange gains and losses[8] - Total operating costs increased to ¥593,128,554.56, up 4.8% from ¥566,029,314.24 in the previous period[23] - The company reported an increase in asset impairment losses by 411.86%, totaling approximately ¥996.08 thousand, primarily due to changes in inventory price provisions[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 45,627[12] - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds a 34.34% stake, amounting to approximately 211.71 million shares[12] - The company did not distribute dividends to minority shareholders during this period, marking a 100% decrease compared to the previous year[12] - As of the end of the reporting period, the company held 6,547,156 shares through a repurchase special securities account, accounting for 1.06% of the total share capital[14] Other Financial Metrics - The company reported a significant decline in fair value changes, with a loss of CNY 3,068,484.95 compared to a gain of CNY 20,208,441.71 in the previous year, a change of -115.18%[8] - Other comprehensive income after tax for the current period is -¥4,995,764.12, compared to ¥32,243,096.89 in the previous period[27] - The company reported a total cash outflow from operating activities of ¥597,505,504.92, compared to ¥731,011,099.38 in the same period last year, indicating a reduction in operational cash outflows[32] - The impact of exchange rate changes on cash and cash equivalents was -¥3,256,817.54, contrasting with a positive impact of ¥5,631,798.27 in Q1 2021[34]

证券代码：002626 证券简称：金达威 公告编号：2022-027 厦门金达威集团股份有限公司 关于召开 2021 年度业绩说明会暨参加 厦门辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）已于 2022 年 4 月 12 日 披露了《2021 年年度报告》。为进一步加强与投资者的互动交流，使广大投资者 能更深入全面地了解公司情况，公司将参加由厦门证监局指导，厦门上市公司协 会联合深圳市全景网络有限公司举办的"厦门辖区上市公司 2021 年年报业绩说 明会暨投资者网上集体接待日"活动，现将本次活动的有关事项公告如下： 一、 活动召开时间 2022 年 5 月 10 日（星期二）14:30-16:00。 二、 活动召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台，采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本次 互动交流。 三、 出席活动的人员 公司出席本次网上集体接待日活动的人员有：公司董事长兼总经 ...

Financial Performance - The company reported a significant impact from the ongoing global COVID-19 pandemic, which has affected supply chains and may influence business operations[5]. - The company's operating revenue for 2021 was CNY 3,616,159,485.95, representing a 3.19% increase from CNY 3,504,406,641.70 in 2020[39]. - The net profit attributable to shareholders for 2021 was CNY 788,857,879.79, a decrease of 17.76% compared to CNY 959,207,761.32 in 2020[39]. - The net profit after deducting non-recurring gains and losses was CNY 774,088,967.81, down 12.07% from CNY 880,300,299.27 in 2020[39]. - The net cash flow from operating activities was CNY 847,331,118.18, a decline of 12.45% from CNY 967,849,312.92 in 2020[39]. - The basic earnings per share for 2021 was CNY 1.29, down 17.83% from CNY 1.57 in 2020[39]. - The total assets at the end of 2021 were CNY 5,847,967,344.97, an increase of 13.49% from CNY 5,152,669,515.78 at the end of 2020[39]. - The net assets attributable to shareholders at the end of 2021 were CNY 3,970,556,485.97, reflecting a growth of 15.81% from CNY 3,428,400,989.49 at the end of 2020[41]. - The weighted average return on net assets for 2021 was 19.69%, down from 28.32% in 2020, indicating a decrease of 8.63%[39]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 20%[29]. Market and Competition - Foreign sales accounted for a substantial portion of total sales, exposing the company to exchange rate fluctuations that could affect profitability[6]. - The company faces intense competition in the health supplement industry, which could impact its market position if it fails to enhance its competitive capabilities[8]. - The global consumer health supplement market reached USD 273.24 billion in 2021, with China holding a market share of 17.76% at USD 48.54 billion, projected to grow to USD 62.40 billion by 2025[56]. - The company has become the largest global producer of coenzyme Q10 and ranks among the top three producers of vitamin D3, indicating a strong position in the health supplement industry[58]. - The health supplement market is expected to grow due to rising health awareness among consumers, leading to a diversification of the consumer base beyond just the elderly[156]. - The overall market for dietary supplements in China has significant growth potential, as the awareness and habits of using dietary supplements are still developing compared to developed countries[154]. Strategic Initiatives - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares to all shareholders, based on a total of 616,481,927 shares[17]. - The company is actively seeking to expand its talent pool to meet the demands of its growing business and new ventures[15]. - The company is investing 200 million RMB in R&D for new nutritional supplements and functional beverages, aiming to enhance product offerings[29]. - Market expansion efforts include entering three new international markets, with an expected contribution of 10% to total revenue by 2023[29]. - The company plans to increase its e-commerce presence, targeting a 50% increase in online sales by the end of 2023[29]. - The company aims to strengthen domestic and international sales channels, with a focus on expanding the NMN product line and leveraging e-commerce platforms like Costco.com and Amazon[160]. - The company plans to expand production capacity and raw material layout in 2022, focusing on new technology and product development to enhance production efficiency[159]. - The company is committed to enhancing brand building and marketing efforts through collaboration with professional marketing teams and e-commerce talent[158]. Risk Management - The company acknowledges the risk of goodwill impairment due to acquisitions, which could adversely affect its financial results if the acquired companies perform poorly[14]. - The company is closely monitoring environmental regulations that may increase compliance costs and impact profitability[10]. - The company recognizes the potential for market price fluctuations to affect operational performance, influenced by raw material costs and consumer behavior[7]. - The company is committed to enhancing its internal controls and management practices to mitigate risks associated with its overseas subsidiaries[13]. - The company has implemented strict internal evaluations and management systems for its derivative investments to mitigate risks associated with market fluctuations[143]. Research and Development - The company has implemented various quality management systems, including ISO9001 and FSSC22000, to ensure product quality and reduce risks[12]. - The company holds 135 authorized patents, including 4 in the United States, and has 80 patents pending[93]. - The company is actively pursuing technological collaboration across its business segments to mitigate rising raw material costs and enhance production efficiency[63]. - The company is investing in research and development for innovative technologies aimed at improving operational efficiency and product offerings[200]. Corporate Governance - The company has established a comprehensive governance structure that adheres to legal and regulatory requirements, ensuring effective management and oversight[173]. - The company maintains independence from its controlling shareholder, ensuring autonomous operations in assets, personnel, and business[175]. - The company has implemented a budget management and performance KPI system, with annual budget planning and monthly performance tracking[173]. - The company is committed to social responsibility and stakeholder engagement, aiming for a balanced approach to interests among shareholders, employees, and society[174]. Future Outlook - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[29]. - The company plans to continue expanding its production of Vitamin A and D3, indicating a focus on increasing capacity in these areas[171]. - Future guidance estimates a revenue growth of 18% for 2022, projecting total revenue of approximately 1.42 billion RMB[190]. - The company aims to improve its gross margin from 35% to 40% through operational efficiencies and cost management strategies[190].

Financial Performance - The company's revenue for Q3 2021 was ¥927,635,231.69, a decrease of 3.40% compared to the same period last year[4] - Net profit attributable to shareholders was ¥158,552,126.11, down 47.07% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥179,909,643.43, a decrease of 39.21% compared to the previous year[4] - The basic earnings per share decreased by 46.94% to ¥0.26[4] - The net profit for Q3 2021 was approximately ¥661.81 million, a decrease of 18.3% compared to ¥809.72 million in the same period last year[30] - The company's operating profit for Q3 2021 was approximately ¥791.89 million, down 18.5% from ¥972.29 million in the same quarter last year[33] - The total comprehensive income for Q3 2021 was approximately ¥685.69 million, compared to ¥757.56 million in the same quarter last year, a decrease of 9.5%[30] - The company's tax expenses for Q3 2021 were approximately ¥119.39 million, down from ¥176.30 million in the previous year, a reduction of 32.3%[33] Assets and Liabilities - The total assets increased by 9.71% to ¥5,652,896,874.38 compared to the end of the previous year[5] - The total liabilities amounted to ¥1,840,922,445.78, compared to ¥1,660,372,379.98 at the end of 2020, reflecting an increase of about 10.87%[25] - The total equity attributable to shareholders reached ¥3,751,256,075.04, up from ¥3,428,400,989.49, indicating a growth of approximately 9.43%[25] - The company's long-term borrowings increased to ¥641,676,945.01 from ¥400,473,872.81, representing a significant rise of approximately 60.06%[23] - The company's total liabilities were CNY 2,093,572,650.29, reflecting a stable financial position despite the challenges faced[40] - The company has a total of ¥21.99 million in contract liabilities, indicating future revenue obligations[44] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥639,538,411.01, down 14.08% year-on-year[4] - The company recorded a net cash outflow from investment activities of approximately ¥266.08 million, a decline of 200.45% year-on-year[11] - Cash inflow from financing activities rose by 218.60% to approximately ¥367.04 million, driven by an increase in borrowed funds[11] - The net cash flow from operating activities for Q3 2021 was CNY 639,538,411.01, a decrease of 14.1% compared to CNY 744,335,603.38 in Q3 2020[35] - The total cash outflow from investing activities was CNY 269,933,898.43, compared to CNY 882,958,374.26 in the previous year, indicating a significant reduction in investment spending[35] - The net cash flow from financing activities was -CNY 447,842,583.78, an improvement from -CNY 784,340,424.86 in Q3 2020, reflecting better management of financing costs[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 43,158[14] - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds a 34.34% stake, amounting to 211,712,732 shares[14] Operational Highlights - Operating income decreased by 86.35% to approximately ¥2.25 million, primarily due to a reduction in government subsidies[11] - The company reported a significant increase in long-term borrowings by 60.23% to ¥641,676,945.01[9] - The company plans to expand its production capacity with investments in new projects, including 800 tons of Vitamin A oil and 200 tons of Vitamin D3 oil[11] - The company reported a decrease in sales prices for coenzyme Q10 and vitamin A, alongside an increase in raw material costs, impacting profitability[18] Inventory and Costs - Total operating costs rose to ¥1,897,733,231.84, up from ¥1,659,482,637.36, indicating an increase of approximately 14.36%[26] - Inventory as of September 30, 2021, was ¥786,326,190.08, compared to ¥690,065,656.34 at the end of 2020, marking an increase of about 13.93%[21] - The company's inventory stood at CNY 690,065,656.34, remaining stable compared to previous periods, indicating effective inventory management[40] Research and Development - Research and development expenses rose to approximately ¥55.75 million, an increase of 13.1% from ¥49.21 million in the previous year[33]

证券代码：002626 证券简称：金达威 公告编号：2021-053 厦门金达威集团股份有限公司关于参加 2021 年度 厦门辖区上市公司投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，厦门金达威集团股份有限公司（以下简称"公司"）将参加由厦门证监局 指导，厦门上市公司协会联合深圳市全景网络有限公司举办的"2021 年度厦门 辖区上市公司投资者网上集体接待日"活动，现将本次活动的有关事项公告如下： 一、活动召开时间 2021 年 9 月 7 日（星期二）15:00-17:00。 二、 活动召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台，采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本次 互动交流。 三、 出席活动的人员 公司出席本次网上集体接待日活动的人员有：公司董事长兼总经理江斌先 生，董事、副总经理兼财务总监洪航先生，副总经理兼董事会秘书洪彦女士。 欢迎广大投资者积极参与。 特此公 ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,776,962,820.59, representing a 10.48% increase compared to CNY 1,608,443,823.54 in the same period last year[44]. - The net profit attributable to shareholders of the listed company was CNY 506,734,950.48, a 2.43% increase from CNY 494,726,395.28 year-on-year[44]. - The net profit after deducting non-recurring gains and losses was CNY 478,580,881.93, up 6.31% from CNY 450,179,774.01 in the previous year[44]. - The total assets at the end of the reporting period were CNY 5,479,052,836.95, reflecting a 6.33% increase from CNY 5,152,669,515.78 at the end of the previous year[44]. - The net assets attributable to shareholders of the listed company increased by 4.54% to CNY 3,583,895,374.90 from CNY 3,428,400,989.49 at the end of the previous year[44]. - The basic earnings per share for the reporting period was CNY 0.83, a 2.47% increase compared to CNY 0.81 in the same period last year[44]. - The weighted average return on equity was 13.76%, down from 15.68% in the previous year, a decrease of 1.92%[44]. - The company achieved a revenue of 1.777 billion CNY in the first half of 2021, representing a year-on-year growth of 10.48%[60]. - The net profit attributable to shareholders was 507 million CNY, an increase of 2.43% year-on-year, while the net profit excluding non-recurring gains and losses was 479 million CNY, up 6.31%[60]. Market Expansion and Product Development - Future outlook indicates a projected revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[32]. - The company is investing 200 million RMB in R&D for new nutritional products, focusing on dietary supplements and functional beverages[32]. - Market expansion efforts include entering three new international markets, aiming for a 10% increase in overseas sales by the end of 2022[32]. - The company has completed the acquisition of a 30% stake in a leading health supplement brand, expected to enhance market share and product offerings[32]. - The company plans to launch a new line of plant-based protein products, targeting a growing segment of health-conscious consumers[32]. - The company is expanding its talent acquisition strategies to meet the demands of its growing business and new market opportunities[18]. - The company has completed the construction of a 500-ton coenzyme Q10 expansion project and is actively developing the vitamin K2 raw material market[61]. - The company launched 9 new formula products under Doctor's Best and 3 new products under Zipfizz during the reporting period[66]. Environmental Compliance and Sustainability - Environmental protection investments amounted to CNY 6.55914 million during the reporting period, focusing on wastewater treatment and emissions control[145]. - The company achieved compliance with pollution discharge standards for all monitored pollutants, including a total wastewater discharge of 11.193 tons of COD and 0.401 tons of ammonia nitrogen[142]. - The company has implemented various waste gas treatment facilities, including water mist spraying and RTO thermal oxidation systems, to ensure emissions meet regulatory standards[148]. - The company has established a comprehensive waste treatment system, including incineration facilities for organic residues and professional disposal services[149]. - The company has successfully maintained compliance with all environmental discharge standards across its operations, including for hazardous waste incineration[144]. - The company has made significant investments in pollution control technologies, including a dual-phase alkaline absorption system for organic waste gas[150]. - The company has implemented a self-monitoring plan for environmental monitoring, with a 100% equipment operation rate and 100% data transmission for key wastewater parameters monitored every two hours[160]. - The company received an administrative penalty of RMB 530,000 for failing to have environmental protection facilities accepted before production, but this was deemed to have a minor impact on operations[161]. Risks and Challenges - The company reported a loss of 654,522.90 CNY from its recent investments, indicating challenges in achieving expected returns[122]. - The company acknowledges risks related to goodwill impairment from acquisitions, which could adversely affect financial performance[15]. - The company faces potential environmental protection costs due to stricter regulations, which could impact profitability[11]. - The company is closely monitoring market price fluctuations and their impact on operational performance, emphasizing the need for strategic pricing[7]. - The company has established a management system for foreign exchange hedging and interest rate swaps, ensuring compliance with relevant laws and regulations[130]. - The company actively monitors potential risks and adjusts strategies accordingly based on specific circumstances[134]. Strategic Partnerships and Collaborations - Strategic partnerships with local distributors are expected to improve supply chain efficiency and reduce costs by 15%[32]. - The company has established a new subsidiary, Jin Dawei Biotechnology (Jiangsu) Co., Ltd., which had no significant impact on overall operations and performance during the reporting period[132]. - The company has engaged in multiple lease agreements for equipment, with terms ranging from 60 to 130 months[188]. Financial Management and Investments - The company plans not to distribute cash dividends or issue bonus shares, focusing on reinvestment[20]. - The company reported a total investment of 9,200,000.00 CNY during the reporting period, marking a 100% increase compared to the previous year[122]. - The company has restricted cash amounting to 129,686,646.55 CNY due to guarantees and international letters of credit[121]. - The company has a total of 1,376 million yuan in joint liability guarantees for Nantong Chengxin Amino Acid Co., Ltd., which is not yet fulfilled[193]. - The total amount of external guarantees provided by the company and its subsidiaries, excluding guarantees to subsidiaries, is 1,376 million yuan[193]. Product Portfolio and Sales Performance - The company has a diverse product portfolio, including over 300 products, with Coenzyme Q10 and Glucosamine being top sellers on platforms like Amazon and iHerb[75]. - The brand Doctor's Best saw a 50.94% year-on-year increase in domestic sales of nutritional health products in the first half of 2021[65]. - Zipfizz's revenue for the first half of 2021 was $31.67 million, a year-on-year decrease of 20.50%, with net profit dropping to $2.78 million, down 43.04%[68]. - The company employs a mixed sales model, combining direct sales and distribution, to expand its market reach both domestically and internationally[78]. - The company expanded its e-commerce and new retail channels, establishing 57 distribution clients and 214 store group clients domestically, along with 17 duty-free store partnerships in Hainan[63].